Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

Eli Lilly and Company has developed an app for people living with Type II diabetes who use Trulicity, the company’s once-per-week injectable diabetes medication that also works with a click-activated ...

In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received ...

Medicare Part D and some Medicare Advantage (Part C) plans may cover Trulicity for managing type 2 diabetes, but coverage specifics depend on the plan’s formulary (drug list). Medicare typically does ...

@2024 - All Right Reserved.

Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...

News 8 On Your Side is investigating a critical drug shortage frustrating diabetics who need the medicine.Investigator Susan Shapiro looked into the shortage and what the drug maker had to say about ...